DUBLIN, January 27, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/p54ckt/the_market_for) has announced the addition of the "The Market for Personalized Gene Therapy Treatments for Cancer" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
The Market for Personalized Gene Therapy Treatments for Cancer
This report, The Market for Personalized Gene Therapy Treatments For Cancer provides an exhaustive review of the market potential for relatively new approach in cancer research. It involves modification of genes instead of using a surgical method or chemical drug product. Essentially, gene therapies replace an abnormal gene with a normal gene, or changes the response of a gene (turn on or off). Not all of the approaches to gene therapy are the same, and different cancers appear to respond better to different therapies.
Several gene therapy technologies have the ability to work in combination with other treatment options to enhance the effectiveness of a therapeutic regimen. Gene therapy is also designed to target specific cells making treatment much less damaging to healthy cells.
This report discusses those treatments and estimates market size and market potential for personalized medicine using gene therapy. As part of its data offering, the report provides disease incidence, gene therapy product developments and market forecasts for the following types of cancer:
- Bladder Cancer
- Brain Cancer
- Breast Cancer
- Head & Neck
- Colorectal Cancer
- Leukemia Cancer
- Liver Cancer
- Lung Cancer
- Lymphoma
- Melanoma
- Leukemia
- Pancreatic Cancer
- Prostate Cancer
- Ovarian Cancer
- Other Cancer
In addition the report provides:
- Overview of Gene Therapy
- Overall Market Size and Forecast
- Cancer Therapeutic Market Totals
- Discussion of Somati vs. Germ Line Gene Therapy
- R&D Activities
- Company Profiles
Historically, cancer treatments have been very invasive and detrimental process to the body. However, there are numerous new techniques available for those with cancer that are not as invasive and detrimental to the body as a whole. These treatments range from the severely alternative to the more traditional. Newer alternative treatments are more precise and much less invasive as some of the traditional methods.
Gene therapy is the most prominent new form of these alternative treatments. It is being studied as a way to change how a cell functions, for example, by stimulating the cells of the immune system to attack cancer cells.
Companies discussed in this report include those which have registered trials in Phase I through Phase III development and have promising development activities.
These include:
- Adaptimmune Ltd.
- Advantagene, Inc.
- Amgen, Inc.
- Bellicum Pharmaceuticals, Inc.
- BioCancell Ltd.
- Blubird Bio
- Celgene
- Celsion Corporation
- Chengdu Shi Endor Biological Engineering Technology Co., Ltd.
- Cold Genesys, Inc.
- Genprex, Inc.
- MaxiVax SA
- Momotaro-Gene, Inc.
- MultiVir, Inc.
- OncoSec Medical, Inc.
- Sevion Therapeutics, Inc.
- SynerGene Therapeutics, Inc.
- Takara Bio, Inc.
- Tocagen, Inc.
- VBL Therapeutics Ltd.
- Ziopharm Oncology, Inc.
Key Topics Covered:
EXECUTIVE SUMMARY
GENE THERAPY OVERVIEW
CANCER AND GENE THERAPY
GENE THERAPY OUTLOOK IN BLADDER CANCER
GENE THERAPY OUTLOOK IN BRAIN CANCER
GENE THERAPY OUTLOOK IN BREAST CANCER
GENE THERAPY OUTLOOK IN COLORECTAL CANCER
GENE THERAPY OUTLOOK IN HEAD & NECK CANCER
GENE THERAPY OUTLOOK IN LEUKEMIA
GENE THERAPY OUTLOOK IN LIVER CANCER
GENE THERAPY OUTLOOK IN LUNG CANCER
GENE THERAPY OUTLOOK IN LYMPHOMA
GENE THERAPY OUTLOOK IN MELANOMA
GENE THERAPY OUTLOOK IN OVARIAN CANCER
GENE THERAPY OUTLOOK IN PANCREATIC CANCER
GENE THERAPY OUTLOOK IN PROSTATE CANCER
GENE THERAPY AND OTHER CANCERS
GENE THERAPY IN CANCER MARKET SUMMARY AND OUTLOOK
INDUSTRY PARTICIPANTS AND CONTRIBUTORS
Companies Mentioned:
- Advantagene, Inc.
- Amgen, Inc.
- Bellicum Pharmaceuticals, Inc.
- BioCancell Ltd.
- Blubird Bio
- Celgene
- Celsion Corporation
- Chengdu Shi Endor Biological Engineering Technology Co., Ltd.
- Cold Genesys, Inc.
- Genprex, Inc.
- MaxiVax SA
- Momotaro-Gene, Inc.
- MultiVir, Inc.
- OncoSec Medical, Inc.
- Sevion Therapeutics, Inc.
- SynerGene Therapeutics, Inc.
- Takara Bio, Inc.
- Tocagen, Inc.
- VBL Therapeutics Ltd.
- Ziopharm Oncology, Inc.
- daptimmune Ltd.
For more information visit http://www.researchandmarkets.com/research/p54ckt/the_market_for
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
